Phase 1 N=28 Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects
Healthy
Primary: Number of Treatment-Emergent Adverse Events (TEAEs) After a Single Dose of CD388 — 7; 3; 6; 2 events
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=16 Evaluating the Benefits of Physiologic Insulin Delivery
Type 1 Diabetes
Primary: Glucagon Response to Induced Hypoglycemia — 4.8; 8.8; 5.8; 4.2 pg/mL
Phase 1 N=56 Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Advanced Solid Tumors · Metastatic Melanoma
Primary: Maximum Concentration (Cmax) of Plasma Midazolam on Day -7, Day 1, and Day 14 — 9.45; 11.1; 2.44 nanograms per milliliter (ng/mL)
Phase 1 N=4 MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0 Participants
Phase 1 N=32 A Study of Maribavir Pediatric Formulation in Healthy Adult Participants
Healthy Volunteers
Primary: Parts 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Maribavir — 12.6; 10.4; 5.98; 10.2 microgram per milliliter (mcg/mL)
Phase 1 N=34 Imaging the Neuroimmune System in PTSD
Post Traumatic Stress Disorder
Primary: Baseline TSPO Availability — 5.11; 4.75; 5.07; 4.38 mL/cm3
Phase 1 N=61 Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
Primary: Number of Participants Who Experienced Dose-Limiting Toxcity (DLT) — 0; 0; 1; 1 Participants
Phase 1 N=18 A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)
Moderate Renal Impairment
Primary: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-Inf) of MK-0616 — 453; 369 hour*nmol/Liter
Phase 1 N=29 Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
Alzheimer's Disease
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 3; 8; 5; 1 Participants
Phase 1 N=73 A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Advanced Solid Tumors · Solid Tumors · Ovarian Cancer
Primary: Area Under the Plasma Concentration-Time Profile From Time 0 to 24 Hours (AUC24) of Talazoparib After Multiple Dosing Under Fasted Conditions — 178.7; 173.0…
Phase 1 N=226 Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines
Poliomyelitis
Primary: Number of Participants With Serious Adverse Events (SAEs) — 0; 0; 0; 0 Participants
Phase 1 N=129 A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers
Advanced Solid Tumors · Metastatic Colon Cancer · Metastatic Breast Cancer
Primary: Dose Escalation Phase: Number of Participants With Dose-limiting Toxicities (DLTs) — 1; 0 Participants
Phase 1 N=14 A Study to Evaluate the Safety and Tolerability of ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal Detachment
Rhegmatogenous Retinal Detachment - Macula Off
Primary: Adverse Event (AE) Reporting — 3; 3; 3; 2 Participants
Phase 1 N=68 Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.
Osteopenia · Osteoporosis · Bone Disease
Primary: Number of Participants With Dose-Limiting or Intolerable Treatment Related Adverse Events (AEs) — 0; 0; 0; 0 Participants
Phase 1 N=6 A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men
Healthy Participants
Primary: Total Recovery of Radioactivity in Urine, Feces and Both Routes Combined, as Percentage of Orally Administered Radioactive Dose of [14C]PF-07081532 — 4.7; 78.6; 83.4…